CAS 41575-94-4|Carboplatin
Introduction：Basic information about CAS 41575-94-4|Carboplatin, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Carboplatin | ||
|---|---|---|---|
| CAS Number | 41575-94-4 | Molecular Weight | 371.254 |
| Density | / | Boiling Point | 366.4ºCat 760 mmHg |
| Molecular Formula | C6H12N2O4Pt | Melting Point | 228-230ºC |
| MSDS | ChineseUSA | Flash Point | 189.6ºC |
| Symbol | GHS07, GHS08 | Signal Word | Danger |
Names
| Name | carboplatin |
|---|---|
| Synonym | More Synonyms |
Carboplatin BiologicalActivity
| Description | Carboplatin (NSC 241240) is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death. Carboplatin (NSC 241240) is a derivative of cisplatin and a potent anti-cancer agent. |
|---|---|
| Related Catalog | Signaling Pathways >>Autophagy >>AutophagySignaling Pathways >>Cell Cycle/DNA Damage >>DNA Alkylator/CrosslinkerSignaling Pathways >>Cell Cycle/DNA Damage >>DNA/RNA SynthesisResearch Areas >>Cancer |
| Target | DNA Alkylator[1] |
| In Vitro | Carboplatin is an antitumor agent, with an increased DNA-binding activity in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts[1]. Carboplatin is less cytotoxic to human ovarian cells such as A2780, SKOV3, IGROV1 and HX62 than 17-AAG, with IC50s of 6.177, 12.442, 2.233 and 116.068 μM, respectively. Moreover, Carboplatin does not affect HSP90 or change the activity of 17-AAG to inhibit HSP90[2]. Carboplatin reduces the viability of Brca1 (IC50, 3.4 μM) and Brca2 cells (IC50, 1.9 μM). Carboplatin (25 μM) combined with ABT-888 also shows an apoptotic effect in BRCA1 cells[3]. |
| In Vivo | Carboplatin (60 mg/kg, i.p.) shows a modest effect on the tumor, but significantly inhibits tumor growth in combination with 17-AAG in mice bearing A2780 human ovarian cancer xenografts[2]. Carboplatin (25 mg/kg, p.o.) combined with ABT-888 delays tumor growth in Brca2 xenografts[3]. |
| Cell Assay | Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying the effect of sequence of exposure to 17-AAG or Carboplatin, cells are exposed to increasing concentrations of 17-AAG or Carboplatin for 24 h. A period of 24-h exposure to the first agent is chosen so that the A2780 cells will be exposed to the first drug for at least one doubling time (18-24 h). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 h) or medium is added for 96 h. SRB assays are carried out. All experiments are carried out in triplicate[2]. |
| Animal Admin | Mice[2] The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) by injecting 4 × 106 cells in each flank. Mice with established tumors corresponding to a mean volume of 0.69 mm3 are randomized into groups (six animals each) for treatment with either control vehicle (43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water) days 1-4, 17-AAG (80 mg/kg intraperitonially, days 1-4), Carboplatin (60 mg/kg IP day 0) or a combination of 17-AAG (80 mg/kg IP days 1-4) and Carboplatin (60 mg/kg IP day 0). Tumor growth is assessed three times weekly and tumor volumes are calculated according to a validated formula: volume = 4.19 × (a/4 + b/4)3, where a is the longer and b the shorter diameter. Tumor volumes are then expressed as a proportion of the volume at the start of treatment (relative tumor volume)[2]. |
| References | [1]. Natarajan G, et al. Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem Pharmacol. 1999 Nov 15;58(10):1625-9. [2]. Banerji U, et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol. 2008 Oct;62(5):769-78. [3]. Clark CC, et al. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther. 2012 Sep;11(9):1948-58. [4]. Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116. |
Chemical & Physical Properties
| Boiling Point | 366.4ºCat 760 mmHg |
|---|---|
| Melting Point | 228-230ºC |
| Molecular Formula | C6H12N2O4Pt |
| Molecular Weight | 371.254 |
| Flash Point | 189.6ºC |
| Exact Mass | 371.044495 |
| PSA | 59.08000 |
| LogP | 0.81700 |
| InChIKey | VSRXQHXAPYXROS-UHFFFAOYSA-N |
| SMILES | O=C(O)C1(C(=O)O)CCC1.[NH2-].[NH2-].[Pt+2] |
| Storage condition | Store at RT |
| Stability | Stable. Incompatible with strong oxidizing agents. |
| Water Solubility | Sparingly soluble in water, very slightly soluble in acetone and in ethanol (96 per cent). | Soluble in water. |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 343 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 72 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 60900 ug/kg
- TOXIC EFFECTS :
- Sense Organs and Special Senses (Eye) - effect, not otherwise specified Gastrointestinal - hypermotility, diarrhea Nutritional and Gross Metabolic - weight loss or decreased weight gain
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 118 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 89360 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Unreported
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 180 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- >31200 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Unreported
- SPECIES OBSERVED :
- Mammal - species unspecified
- DOSE/DURATION :
- 158 mg/kg
- TOXIC EFFECTS :
- Tumorigenic - active as anti-cancer agent
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 70 mg/kg/2W-I
- TOXIC EFFECTS :
- Lungs, Thorax, or Respiration - changes in lung weight Endocrine - changes in spleen weight Blood - changes in platelet count
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 140 mg/kg/26W-I
- TOXIC EFFECTS :
- Blood - normocytic anemia Blood - changes in bone marrow (not otherwise specified) Blood - changes in leukocyte (WBC) count
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 60 mg/kg/5D-I
- TOXIC EFFECTS :
- Gastrointestinal - alteration in gastric secretion Gastrointestinal - other changes Blood - hemorrhage
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 24 mg/kg
- SEX/DURATION :
- female 6-9 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 24 mg/kg
- SEX/DURATION :
- female 6-9 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- TYPE OF TEST :
- Micronucleus test
- TYPE OF TEST :
- DNA damage
- TYPE OF TEST :
- DNA inhibition
- TYPE OF TEST :
- Mutation test systems - not otherwise specified
- TYPE OF TEST :
- Cytogenetic analysis
MUTATION DATA - TYPE OF TEST :
- Morphological transformation
- TEST SYSTEM :
- Rodent - hamster Kidney
- DOSE/DURATION :
- 25 umol/L
- REFERENCE :
- EJCODS European Journal of Cancer and Clinical Oncology. (Pergamon Press, c/o Elsevier Science, 660 White Plains Rd., Tarrytown, NY 10591) V.17(7)- 25, 1981-89. For publisher information, see EJCAEL Volume(issue)/page/year: 25,27,1989 *** REVIEWS *** TOXICOLOGY REVIEW JPMSAE Journal of Pharmaceutical Sciences. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.50- 1961- Volume(issue)/page/year: 65,315,1976
- TYPE OF TEST :
- Morphological transformation
- TEST SYSTEM :
- Rodent - hamster Kidney
- DOSE/DURATION :
- 25 umol/L
- REFERENCE :
- EJCODS European Journal of Cancer and Clinical Oncology. (Pergamon Press, c/o Elsevier Science, 660 White Plains Rd., Tarrytown, NY 10591) V.17(7)- 25, 1981-89. For publisher information, see EJCAEL Volume(issue)/page/year: 25,27,1989 *** REVIEWS *** TOXICOLOGY REVIEW JPMSAE Journal of Pharmaceutical Sciences. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.50- 1961- Volume(issue)/page/year: 65,315,1976
Safety Information
| Symbol | GHS07, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H302 + H312 + H332-H317-H334-H340-H360 |
| Precautionary Statements | P201-P261-P280-P308 + P313 |
| Personal Protective Equipment | Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | T:Toxic |
| Risk Phrases | R46;R61;R20/21;R42/43 |
| Safety Phrases | S53-S22-S26-S36/37/39-S45 |
| RIDADR | UN 2811 |
| WGK Germany | 3 |
| RTECS | TP2300000 |
| HS Code | 2843900030 |
Customs
| HS Code | 2843900030 |
|---|
Articles207
More Articles| Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget 5(21) , 10434-45, (2014) The successes of targeted therapeutics against EGFR and ALK in non-small cell lung cancer (NSCLC) have demonstrated the substantial survival gains made possible by precision therapy. However, the majo... | |
| Graphene oxide - gelatin nanohybrids as functional tools for enhanced Carboplatin activity in neuroblastoma cells. Pharm. Res. 32 , 2132-43, (2015) Preparation of Nanographene oxide (NGO) - Gelatin hybrids for efficient treatment of Neuroblastoma.Nanohybrids were prepared via non-covalent interactions. Spectroscopic tools have been used to discri... | |
| CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome. Oncotarget 5(15) , 6191-205, (2014) Malignant mesothelioma is a deadly tumor whose diagnosis and treatment remain very challenging. There is an urgent need to advance our understanding of mesothelioma biology and to identify new molecul... |
Synonyms
| Diammine[1,1-cyclobutanedicarboxylato(2-)-κO,O]platinum |
| cis-Diammine(1,1-cyclobutanedicarboxylato) platinum |
| Platinum(2+) 1,1-cyclobutanedicarboxylate diammoniate |
| cbdca |
| MFCD00070464 |
| (SP-4-2)-diammine(1,1-cyclobutanedicarboxylato)platinum(II) |
| [Cyclobutane-1,1-dicarboxylato(2-)-κO,O]platinum diammoniate |
| cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) |
| [1,1-Cyclobutanedicarboxylato(2-)-κO,O]platinum diammoniate |
| Platinum, [1,1-cyclobutanedicarboxylato(2-)-κO,κO]-, ammoniate (1:2) |
| JM-8 |
| PARAPLATIN |
| cis-diammine(cyclobutane-1,1-dicarboxylato)platinum(II) |
| PARAPLATIN(R) |
| CARBONPLATIN |
| cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II) |
| CARBOPLATINUM |
| diammine[cyclobutane-1,1-dicarboxylato(2-)-κ2O1,O1]platinum |
| cis-diammmine(1,1-cyclobutanedicarboxylato)platinum(II) |
| Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-κO,κO]- |
| EINECS 255-446-0 |
| Carboplatin |
| diammine(cyclobutane-1,1-dicarboxylato)platinum(II) |
| platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-κO1,κO1]- |
